337 related articles for article (PubMed ID: 16284058)
1. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
Hotte SJ; Oza A; Winquist EW; Moore M; Chen EX; Brown S; Pond GR; Dancey JE; Hirte HW
Ann Oncol; 2006 Feb; 17(2):334-40. PubMed ID: 16284058
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
3. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium.
Welch S; Hirte HW; Carey MS; Hotte SJ; Tsao MS; Brown S; Pond GR; Dancey JE; Oza AM
Gynecol Oncol; 2007 Aug; 106(2):305-10. PubMed ID: 17537491
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Jimeno A; Rudek MA; Purcell T; Laheru DA; Messersmith WA; Dancey J; Carducci MA; Baker SD; Hidalgo M; Donehower RC
Cancer Chemother Pharmacol; 2008 Mar; 61(3):423-33. PubMed ID: 17429623
[TBL] [Abstract][Full Text] [Related]
5. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
Lara PN; Mack PC; Synold T; Frankel P; Longmate J; Gumerlock PH; Doroshow JH; Gandara DR
Clin Cancer Res; 2005 Jun; 11(12):4444-50. PubMed ID: 15958629
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
7. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Kakolyris S; Kouroussis C; Souglakos J; Mavroudis D; Agelaki S; Kalbakis K; Androulakis N; Vardakis N; Vamvakas L; Georgoulias V
Oncology; 2001; 61(4):265-70. PubMed ID: 11721172
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
Kortmansky J; Shah MA; Kaubisch A; Weyerbacher A; Yi S; Tong W; Sowers R; Gonen M; O'reilly E; Kemeny N; Ilson DI; Saltz LB; Maki RG; Kelsen DP; Schwartz GK
J Clin Oncol; 2005 Mar; 23(9):1875-84. PubMed ID: 15699481
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of docetaxel and topotecan in patients with solid tumors.
Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
Sausville EA; Arbuck SG; Messmann R; Headlee D; Bauer KS; Lush RM; Murgo A; Figg WD; Lahusen T; Jaken S; Jing X; Roberge M; Fuse E; Kuwabara T; Senderowicz AM
J Clin Oncol; 2001 Apr; 19(8):2319-33. PubMed ID: 11304786
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
Kummar S; Gutierrez ME; Gardner ER; Figg WD; Melillo G; Dancey J; Sausville EA; Conley BA; Murgo AJ; Doroshow JH
Cancer Chemother Pharmacol; 2010 Jan; 65(2):383-9. PubMed ID: 19894051
[TBL] [Abstract][Full Text] [Related]
17. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Creemers GJ; Gerrits CJ; Eckardt JR; Schellens JH; Burris HA; Planting AS; Rodriguez GI; Loos WJ; Hudson I; Broom C; Verweij J; Von Hoff DD
J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
20. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
